Production Of Complementary DNA Representing Hepatitis A Viral Sequences By Recombinant DNA Methods And Uses Therefor
Description of Invention:
A method for the production and use of single- and double-stranded (ds) cDNA representing hepatitis A virus (HAV) sequences has been discovered, including an infectious, full-length cDNA clone of wild-type HAV. Large quantitites of the novel HAV cDNA can be harvested at a relatively low cost via insertion of the cDNA molecules into a recombinant DNA vector and subsequent transformation in appropriate cells; modification of bacteria by genetic engineering permits for the production of ds HAV cDNA. The cDNA molecules hold substantial diagnostic potential because they are highly specific and very sensitive to HAV; they can also be used in the production of either HAV antigen or antibodies to HAV antigen for possible vaccine development. Currently, no vaccine is available for protection against HAV infection.
Inventors:
J Ticehurst (NIAID) SM Feinstone (NIAID) RH Purcell (NIAID) SU Emerson (NIAID) et al.
Patent Status:
DHHS Reference No. E-325-1983/2 --
U.S. Patent 5,516,630 issued 14 May 1996
U.S. Patent 5,849,562 issued 15 Dec 1998
